Kari Keese - Axonics Modulation Chief Officer
Executive
Kari Keese is Chief Officer of Axonics Modulation Technologies
| Age | 39 |
| Phone | 949 396 6322 |
| Web | https://www.axonics.com |
Kari Keese Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kari Keese against Axonics Modulation stock is an integral part of due diligence when investing in Axonics Modulation. Kari Keese insider activity provides valuable insight into whether Axonics Modulation is net buyers or sellers over its current business cycle. Note, Axonics Modulation insiders must abide by specific rules, including filing SEC forms every time they buy or sell Axonics Modulation'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kari Keese over three months ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese over three months ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese over three months ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese over three months ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 |
Axonics Modulation Management Efficiency
Axonics Modulation's management efficiency ratios could be used to measure how well Axonics Modulation manages its routine affairs as well as how well it operates its assets and liabilities.Axonics Modulation Technologies currently holds 27.62 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics Modulation has a current ratio of 10.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Axonics Modulation's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jill Mason | Orthofix Medical | N/A | |
| Katie Keller | Neuropace | N/A | |
| Trui Hebbelinck | LivaNova PLC | 52 | |
| Matthew III | LivaNova PLC | N/A | |
| Irene Thomas | Neuropace | 55 | |
| Orit Wimpfheimer | Nano X Imaging | 53 | |
| Marcee Maroney | Pulmonx Corp | 55 | |
| Mark Ploof | Medtronic PLC | N/A | |
| Sarah Oliker | CONMED | 43 | |
| Chris Calcaterra | Glaukos Corp | 65 | |
| Kimberly Lockwood | CONMED | N/A | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Irina Ridley | Neuropace | 38 | |
| Anthony Recupero | Si Bone | 66 | |
| Torod Neptune | Medtronic PLC | N/A | |
| Chantal VeillonBerteloot | Integra LifeSciences Holdings | 55 | |
| Natalia Kozmina | LivaNova PLC | N/A | |
| Sumi Shrishrimal | iRhythm Technologies | 45 | |
| Thomas Bures | Bruker | 50 | |
| Stephen Leonard | Integra LifeSciences Holdings | 63 | |
| Tracy Founds | Glaukos Corp | N/A | |
Management Performance
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 |
Axonics Modulation Leadership Team
Elected by the shareholders, the Axonics Modulation's board of directors comprises two types of representatives: Axonics Modulation inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics Modulation's management team and ensure that shareholders' interests are well served. Axonics Modulation's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics Modulation's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfred Ford, Chief Commercial Officer | ||
| Danny Dearen, Chief Operating and Financial Officer | ||
| MD MAS, Chief Officer | ||
| Raymond Cohen, CEO, Director | ||
| Rinda Sama, Chief Officer | ||
| JD Esq, General VP | ||
| Aaron Pettit, General Officer | ||
| Kari Keese, Chief Officer | ||
| John Woock, Chief Marketing Officer | ||
| Neil Bhalodkar, Vice Relations | ||
| Guangqiang Jiang, Chief Officer |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics Modulation a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 51.11 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 87.22 % | |||
| Number Of Shares Shorted | 3.31 M | |||
| Price To Earning | (10.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Axonics Stock
If you are still planning to invest in Axonics Modulation check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Axonics Modulation's history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |